Evidence map›Paper›PMID 35118966›Full record

ArticleTurkish journal of urology2021

Yohimbine as a treatment for erectile dysfunction: A systematic review and meta-analysis.

Dwi Nanda Satriyo Arif Wibowo, Doddy Moesbadianto Soebadi, Mohammad Ayodhia Soebadi

Open access · greenAbstract read
In one paragraph

Article in Turkish journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Multifaced Nature of Yohimbine-A Promising Therapeutic Potential or a Risk?International journal of molecular sciences · 2024
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dwi Nanda Satriyo Arif WibowoDepartment of Urology, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General- Academic Hospital, Surabaya, Indonesia.
Doddy Moesbadianto SoebadiDepartment of Urology, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General- Academic Hospital, Surabaya, Indonesia.
Mohammad Ayodhia SoebadiDepartment of Urology, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General- Academic Hospital, Surabaya, Indonesia.
Airlangga University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, several studies have reported promising results of Yohimbine as a natural supplement for erectile dysfunction (ED). However, several studies suggested that the aphrodisiac effects of the extract were only a placebo or due to the increase in peripheral vascular congestion. In contrast, other studies reported that it could provide excellent curative effects on organic impotence. We aimed to review the efficacy of Yohimbine as a pharmacological treatment for ED and performed a comprehensive systematic search of published articles in PubMed and Science Direct databases for eligible randomized controlled trials comparing Yohimbine to placebo or no treatment for ED patients. A total of eight studies out of 543 studies were included in this review. Both Yohimbine alone (odds ratio [OR] ¼ 2.08, 95% CI 1.30-3.32, P ¼ .002) and combined (OR ¼ 6.35, 95% CI 3.01-13.41, P < .001) showed a significantly greater probability of erectile function improvement compared to the placebo group (OR ¼ 2.87, 95% CI 1.94-4.25, P < .001). Yohimbine alone did not show a significant difference in the rate of improved sexual function (P ¼ .07); however, the pooled results of both subgroups indicated a higher rate of improved sexual function (OR ¼ 2.65, 95% CI 1.43-4.92, P ¼ .002). Sole administration of Yohimbine and its combination with other supplements can improve the erectile function in ED patients. However, it is not able to improve the sexual function if not combined with other treatments.

Identifiers

PMID35118966
PMCPMC9612744
OpenAlexW4200485325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.